Skip to content
Back to Investors
Redalpine

Redalpine

Venture Capital

Redalpine is an investment firm whose portfolio includes companies such as 9fin.

Portfolio

6

companies

AUM

£1.0B

under management

Investment by month

By category

  • FinTech£195M
  • Uncategorised£26.8M
  • AI/ML£18.9M
  • MedTech£6.5M
  • HealthTech£5.5M

By location

  • London£253M

Portfolio companies

9fin

9fin

9fin provides a data and analytics platform for debt capital markets.

A

Apoha

Apoha builds a behavioural data layer for molecular and material science.

DaltonTx

DaltonTx

DaltonTx develops adaptive AI platforms to accelerate drug discovery for pharmaceutical and biotech organisations.

Hypervision Surgical

Hypervision Surgical

Hypervision Surgical develops an advanced surgical imaging and data analytics platform.

Level Zero Health

Level Zero Health

Level Zero Health develops wearable technology for continuous hormone monitoring.

Synthesized

Synthesized

Synthesized automates test data and infrastructure for enterprise software quality assurance.


Team

AL

Aleksandra Laska

Partner

Daniel Dillinger

Daniel Dillinger

Investment Manager

Daniel brings venture capital investment experience from Redalpine, alongside board and advisory roles across multiple startups.

LinkedIn
Philip Kneis

Philip Kneis

Investor

Philip invests at Redalpine and holds board observer or director roles at several early stage companies. He previously held a leadership role at the University of Oxford.

LinkedIn
Marc Moesser

Marc Moesser

Investment Manager

Marc is a principal at Redalpine, where he holds investor and board roles across several companies following a PhD in machine learning from Oxford.

LinkedIn
DG

Daniel Graf

General Partner

LinkedIn

Recent investments

Series A
£14.9M

Redalpine led the Series A round to support team expansion and the rollout of new capabilities.

"Synthesized is tackling one of the most urgent and overlooked challenges in the age of AI: how to test, validate, and trust what we build. Their platform doesn’t just generate high-quality test data – it lays the foundation for a new class of autonomous QA agents that will transform how modern software is verified and shipped. We believe Synthesized can become the infrastructure layer for intelligent, automated quality assurance across regulated and mission-critical systems."
— Daniel Graf, General Partner
Seed
£4.0M

The seed round was backed by Redalpine, IQ Capital Partners, and Seedcamp.

"AI offers an opportunity to transform drug discovery, but it is still incredibly challenging for organisations to build their own capabilities. DaltonTx exists to change that. We are solving high-impact challenges with adaptive AI-enabled systems that integrate into scientific workflows, evolve with every experiment, and give organisations lasting AI capability."
— Garry Pairaudeau, Co-Founder
Pre-Seed
£5.5M

Redalpine led the pre-seed round to help the startup bring its wearable hormone sensors to market and expand its team.

"We did it for blood pressure and will do it again for hormones. Continuous hormone measurement is one of the holy grails of diagnostics, and as fundamental science transitions to engineering, we couldn’t be more excited to back Level Zero Health in their mission to transform hormone tracking with their novel biosensor – paving the way for a new era of personalized health management."
— Philip Kneis, Investor